PASS Targets: Ligand-based multi-target computational system based on a public data and naïve Bayes approachFootnote

^$Presented at the 8^th International Symposium on Computational Methods in Toxicology and Pharmacology Integrating Internet Resources, CMTPI-2015, June 21–25, 2015, Chios, Greece.

References

• T.A. Kenakin, Pharmacology Primer: Techniques for More Effective and Strategic Drug Discovery, Elsevier, San Diego, 2014, pp. 281–318.
   Google Scholar
• A.V. Veselovsky, M.S. Zharkova, V.V. Poroikov, and M.C. Nicklaus, Computer-aided design and discovery of protein–protein interaction inhibitors as agents for anti-HIV therapy, SAR QSAR Environ. Res. 25 (2014), pp. 457–471.
   PubMed Web of Science ®Google Scholar
• T. Kalliokoski, C. Kramer, and A. Vulpetti, Quality issues with public domain chemogenomics data, Mol. Inf. 32 (2013), pp. 898–905.
   Web of Science ®Google Scholar
• C. Kramer, T. Kalliokoski, P. Gedeck, and A. Vulpetti, The experimental uncertainty of heterogeneous public Ki data, J. Med. Chem. 55 (2012), pp. 5165–5173.
   PubMed Web of Science ®Google Scholar
• T. Kalliokoski, C. Kramer, A. Vulpetti, and P. Gedeck, Comparability of mixed IC50 data–a statistical analysis, PloS One 8 (2013), e61007.
   PubMed Web of Science ®Google Scholar
• J. Gasteiger, Some solved and unsolved problems of chemoinformatics, SAR QSAR Environ. Res. 25 (2014), pp. 443–455.
   PubMed Web of Science ®Google Scholar
• J.L. Reymond, The chemical space project, Acc. Chem. Res. 48 (2015), pp. 722–730.
   PubMed Web of Science ®Google Scholar
• J.P. Overington, B. Al-Lazikani, and A.L. Hopkins, How many drug targets are there?, Nat. Rev. Drug Discov. 5 (2006), pp. 993–996.
   PubMed Web of Science ®Google Scholar
• X. Jalencas and J. Mestres, On the origins of drug polypharmacology, MedChemComm 4 (2013), pp. 80–87.
   Web of Science ®Google Scholar
• J.U. Peters, Polypharmacology–foe or friend?, J. Med. Chem. 56 (2013), pp. 8955–8971.
   PubMed Web of Science ®Google Scholar
• L.M. Bolognesi, Polypharmacology in a single drug: Multitarget drugs, Curr. Med. Chem. 20 (2013), pp. 1639–1645.
   PubMed Web of Science ®Google Scholar
• V. Law, C. Knox, Y. Djoumbou, T. Jewison, A.C. Guo, Y. Liu, and D.S. Wisart, DrugBank 4.0: Shedding new light on drug metabolism, Nucleic Acids Res. 42 (2014), pp. 1091–1097.
   PubMed Web of Science ®Google Scholar
• H. Geppert, M. Vogt, and J. Bajorath, Current trends in ligand-based virtual screening: Molecular representations, data mining methods, new application areas, and performance evaluation, J. Chem. Inf. Model. 50 (2010), pp. 205–216.
   PubMed Web of Science ®Google Scholar
• H. Jasuja, N. Chadha, M. Kaur, and O. Silakari, Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2, SAR QSAR Environ. Res. 25 (2014), pp. 617–636.
   PubMed Web of Science ®Google Scholar
• D.A. Filimonov, A.A. Lagunin, T.A. Gloriozova, A.V. Rudik, D.S. Druzhilovskii, P.V. Pogodin, and V.V. Porikov, Prediction of the biological activity spectra of organic compounds using the PASS online web resource, Chem. Heterocycl. Compd. 50 (2014), pp. 444–457.
   Web of Science ®Google Scholar
• A.P. Bento, A. Gaulton, A. Hersey, L.J. Bellis, J. Chambers, M. Davies, F.A. Krüger, Y. Light, L. Mak, S. McGlinchey, M. Nowotka, G. Papadatos, R. Santos, and J.P. Overington, The ChEMBL bioactivity database: An update, Nucleic Acids Res. 42 (2014), pp. 1083–1090.
   PubMed Web of Science ®Google Scholar
• D.A. Filimonov, V.V. Poroikov, Y. Borodina, and T.A. Gloriozova, Chemical similarity assessment through multilevel neighborhoods of atoms: Definition and comparison with the other descriptors, J. Chem. Inf. Comput. Sci. 39 (1999), pp. 666–670.
   Google Scholar
• A.A. Lagunin, A.S. Stepanchikova, D.A. Filimonov, and V.V. Poroikov, PASS: Prediction of activity spectra for biologically active substances, Bioinformatics. 16 (2000), pp. 747–748.
   PubMed Web of Science ®Google Scholar
• S.M. Ivanov, A.A. Lagunin, P.V. Pogodin, D.A. Filimonov, and V.V. Poroikov, Identification of drug-induced myocardial infarction-related protein targets through the prediction of drug–target interactions and analysis of biological processes, Chem. Res. Toxicol. 27 (2014), pp. 1263–1281.
   PubMed Web of Science ®Google Scholar
• S.M. Ivanov, A.A. Lagunin, P.V. Pogodin, D.A. Filimonov, and V.V. Poroikov, Identification of drug targets related to the induction of ventricular tachyarrhythmia through a systems chemical biology approach, Toxicol. Sci. 145 (2015), pp. 321–336.
   PubMed Web of Science ®Google Scholar
• T.T. Ashburn and K.B. Thor, Drug repositioning: Identifying and developing new uses for existing drugs, Nat. Rev. Drug Discov. 3 (2004), pp. 673–683.
   PubMed Web of Science ®Google Scholar
• T.I. Oprea, J.E. Bauman, C.G. Bologa, T. Buranda, A. Chigaev, B.S. Edwards, J.W. Jarvik, H.D. Gresham, M.K. Haynes, B. Hjelle, R. Hromas, L. Hudson, D.A. Mackenzie, C.Y. Muller, J.C. Reed, P.C. Simons, Y. Smagley, J. Strouse, Z. Surviladze, T. Thompson, O. Ursu, A. Waller, A. Wandinger-Ness, S.S. Winter, Y. Wu, S.M. Young, R.S. Larson, and C. Willman, Drug repurposing from an academic perspective, Drug Discov. Today Ther. Strateg. 8 (2012), pp. 61–69.
   Google Scholar
• Y. Wang, T. Suzek, J. Zhang, J. Wang, S. He, T. Cheng, B.A. Shoemaker, A. Gindulyte, and S.H. Bryant, PubChem BioAssay: 2014 update, Nucleic Acids Res. 42 (2014), pp. D1075–D1082.
   Google Scholar
• D.S. Gryder and M.A. Rogawski, Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons, J. Neurosci. 18 (2003), pp. 7069–7074.
   Google Scholar
• H.S. White, Topiramate: Mechanisms of action, in Antiepileptic Drugs, 5th ed., R.H. Levy, R.H. Mattson, B.S. Meldrum, and E. Perrucca, eds., Lippincott Williams & Wilkins, Philadelphia, 2002, pp. 719–726.
   Google Scholar
• A. Vidal, M. Sabatini, G. Rolland-Valognes, P. Renard, J.C. Madelmont, and E. Mounetou, Synthesis and in vitro evaluation of targeted tetracycline derivatives: Effects on inhibition of matrix metalloproteinases, Bioorg. Med. Chem. 15 (2007), pp. 2368–2374.
   PubMed Web of Science ®Google Scholar
• A. Carnero, High throughput screening in drug discovery, Clin. Transl. Oncol. 8 (2006), pp. 482–490.
   PubMedGoogle Scholar
• A. Karlén, M. Lindh, F. Svensson, W. Schaal, J. Zhang, C. Sköld, and P. Brandt, Towards a benchmarking dataset able to evaluate ligand-and structure-based virtual screening using public HTS data, J. Chem. Inf. Model. 55 (2015), pp. 343–353.
   PubMed Web of Science ®Google Scholar
• P. Cohen, Protein kinases—the major drug targets of the twenty-first century?, Nat. Rev. Drug Discov. 1 (2002), pp. 309–315.
   PubMed Web of Science ®Google Scholar
• W. Peng, T.E. Nielsen, and M.H. Clausen, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol. Sci. 36 (2015), pp. 422–429.
   PubMed Web of Science ®Google Scholar
• S. Knapp and M. Sundström, Recently targeted kinases and their inhibitors—the path to clinical trials, Curr. Opin. Pharmacol. 17 (2014), pp. 58–63.
   PubMed Web of Science ®Google Scholar
• A. Levitzki, Tyrosine kinase inhibitors: Views of selectivity, sensitivity, and clinical performance, Annu. Rev. Pharmacol. Toxicol. 53 (2013), pp. 161–185.
   PubMed Web of Science ®Google Scholar
• UniProt Consortium, UniProt: A hub for protein information, Nucleic Acids Res. 43 (2015), pp. 204–212.
   PubMed Web of Science ®Google Scholar